Back to top
more

Mesa Laboratories (MLAB)

(Real Time Quote from BATS)

$59.26 USD

59.26
89,179

+1.82 (3.17%)

Updated Aug 6, 2025 11:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Mesa Labs (MLAB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -2.02% and 3.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ReWalk Robotics (RWLK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ReWalk (RWLK) delivered earnings and revenue surprises of 12.50% and 38.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 19.23% and 7.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Shockwave Medical (SWAV) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 27.16% and 10.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Paragon 28, Inc. (FNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -10% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -209.09% and 63.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mesa Labs (MLAB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed the most recent trading day at $171.42, moving -1.89% from the previous trading session.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Equity Research

Is Mesa Labs (MLAB) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Mesa Labs (MLAB) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Mesa Labs (MLAB) Tops Q3 Earnings Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?

by Zacks Equity Research

Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.

Zacks Equity Research

Mesa Labs (MLAB) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed at $193.27 in the latest trading session, marking a +0.56% move from the prior day.

Zacks Equity Research

Mesa Labs (MLAB) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed at $193.84 in the latest trading session, marking a +0.96% move from the prior day.

Zacks Equity Research

Mesa Labs (MLAB) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed at $190.51 in the latest trading session, marking a +0.93% move from the prior day.

Zacks Equity Research

Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.

Zacks Equity Research

Mesa Labs (MLAB) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Mesa Labs (MLAB) closed the most recent trading day at $178.79, moving +1.53% from the previous trading session.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Here's Why You Should Buy Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised)

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Zacks Equity Research

Here's Why You Should Retain Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.

Zacks Equity Research

Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

Kevin Cook headshot

Bull of the Day: Mesa Labs (MLAB)

by Kevin Cook

After Q2 results, EPS estimates soar 39% as revenues grow 24% on strong M&A strategies

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy as Inflation Clouds Prospects

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on rising demand for digital health. SWAV, MLAB and DYNT are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is an overhang.